Online inquiry

IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12815MR)

This product GTTS-WQ12815MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MASP2 gene. The antibody can be applied in Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_006610.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10747
UniProt ID O00187
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12815MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ686MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ3908MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ4199MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ7420MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ5418MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ10829MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ2336MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ11894MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW